Severe and refractory peptic ulcer disease: The diagnostic dilemma. Case report and comprehensive review

Digestive Diseases and Sciences

Volumn 50, Issue 11, 2005, Pages 1999-2008

  Guzzo, James L ^a   Duncan, Mona ^a   Bass, Barbara L ^a   Bochicchio, Grant V ^a   Napolitano, Lena M ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Gastrin; Helicobacter pylori; Hypersecretion; Peptic ulcer disease; Zollinger Ellison syndrome

Indexed keywords

PROTON PUMP INHIBITOR; RABEPRAZOLE;

ABDOMINAL RADIOGRAPHY; ADULT; CASE REPORT; CHOLECYSTECTOMY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; GASTRINOMA; HELICOBACTER PYLORI; HUMAN; HYPERGASTRINEMIA; LAPAROTOMY; PEPTIC ULCER; PRIORITY JOURNAL; REVIEW; ROUX Y ANASTOMOSIS; STOMACH ACID SECRETION; STOMACH ANTRUM RESECTION; STOMACH OBSTRUCTION; TRUNCUS VAGOTOMY; ZOLLINGER ELLISON SYNDROME;

ADULT; ANTI-ULCER AGENTS; FEMALE; HELICOBACTER INFECTIONS; HUMANS; PEPTIC ULCER; RECURRENCE; RISK FACTORS;

EID: 27144462583     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-005-2999-5     Document Type: Review

References (42)

1. Soll AH: Medical treatment of peptic ulcer disease. JAMA 275:622, 1996
2. Walsh JH, Peterson WL: The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med333:984, 1995
3. Hopkins RJ, Girardi LS, Turney EA: Relationship between H. pylori eradication and reduced duodenal and gastric ulcer recurrence: A review. Gastroenterology 110:1244, 1996
4. Verma S, Giaffer MH: Helicobacter pylori eradication ameliorates symptoms and improves quality of life in patients on long-term acid suppression. a large prospective study in primary care. Dig Dis Sci 47(7): 1567-1574, 2002
5. Bardhan KD, Nayyar AK, Royston C: History in our lifetime: the changing nature of refractory duodenal ulcer in the era of histamine H2 receptor antagonists. Dig Liver Dis 35(8):529-536, 2003
6. Ford A, Delaney B, Forman D, Moayyedi P: Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev (4):CD003840, 2004
7. Liu CC, Lee CL, Chan CC, Tu TC, Liao CC, Wu CH, Chen TK: Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study. Arch Intern Med 163(17):2020-2024, 2003
8. Bardhan KD, Williamson M, Royston C, Lyon C: Admission rates for peptic ulcer in the trent region, UK, 1972-2000. changing pattern, a changing disease? Dig Liver Dis 36(9):577-588, 2004
9. Miwa H, Sakaki N, Sugano K, Sekine H, Higuchi K, Uemura N, Kato M, Murakami K, Kato C, Shiotani A, Ohkusa T, Takagi A, Aoyama N, Haruma K, Okazaki K, Kusugami K, Suzuki M, Joh T, Azuma T, Yanaka A, Suzuki H, Hashimoto H, Kawai T, Sugiyama T: Recurrent peptic ulcers in patients following successful Helicobacter pylori eradication: a multicenter study of 4940 patients. Helicobacter 9(1):9-16, 2004
10. Lanas AI, Remacha B, Esteva F, et al.: Risk factors associated with refractory peptic ulcers. Gastroenterology 109:1124, 1995
11. Rosenstock S, Jorgensen T, Bonnevie O, Andersen L: Risk factors for peptic ulcer disease: a population based prospective cohort study comprising 2416 Danish adults. Gut 52(2):186-193, 2003
12. Anda RF, Williamson DF, Escobedo LG, Remington PL: Smoking and the risk of peptic ulcer disease among women in the United States. Arch Intern Med 150(7):1437-1441, 1990
13. Reynolds JC, Schoen RE, Maislin G, Zangari GG: Risk factors for delayed healing of duodenal ulcers treated with famotidine and ranitidine. Am J Gastroenterol 89(4):571-580, 1994
14. Laine L: Proton pump inhibitor co-therapy with nonsteroidal antiinflammatory drugs-nice or necessary? Rev Gastroenterol Disord 4 (Suppl 4):S33-S41, 2004
15. Goldstein JL: Challenges in managing NSAID-associated gastrointestinal tract injury. Digestion 69 (Suppl 1):25-33, 2004
16. Lai KC, Lam SK, Chu KM, Hui WM, Kwok KF, Wong BC, Hu HC, Wong WM, Chan OO, Chan CK: Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal antiinflammatory drug users - a randomized trial. Aliment Pharmacol Ther 18(8):829-836, 2003
17. Goddard AF, Logan RP: Diagnostic methods for Helicobacter pylori detection and eradication. Br J Clin Pharmacol 56(3):273-283, 2003
18. Howden CW, Hunt RH: Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 93(12):2330-2338, 1998
19. Branca G, Spanu T, Cammarota G, Schito AM, Gasbarrini A, Gasbarrini GB, Fadda G: High levels of dual resistance to clarithromycin and metronidazole and in vitro activity of levofloxacin against Helicobacter pylori isolates from patients after failure of therapy. Int J Antimicrob Agents 24(5):433-438, 2004
20. Cammarota G, Martino A, Pirozzi G, Cianci R, Branca G, Nista EC, Cazzato A, Cannizzaro O, Miele L, Grieco A, Gasbarrini A, Gasbarrini G: High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther 19(7):789-795, 2004
21. Duck WM, Sobel J, Pruckler JM, Song Q, Swerdlow D, Friedman C, Sulka A, Swaminathan B, Taylor T, Hoekstra M, Griffin P, Smoot D, Peek R, Metz DC, Bloom PB, Goldschmidt S, Parsonnet J, Triadafilopoulos G, Perez-Perez GI, Vakil N, Ernst P, Czinn S, Dunne D, Gold BD: Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 10(6):1088-1094, 2004
22. Fischbach LA, Zanten SV, Dickason J: Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 20(10):1071-1082, 2004
23. Furuta T, Shirai N, Xiao F, Takashita M, Sugimoto M, Kajimura M, Ohashi K, Ishizaki T: High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology 50(54):2274-2248, 2003
24. Ruggiero P, Peppoloni S, Rappuoli R, Del Giudice G: The quest for a vaccine against Helicobacter pylori: how to move from mouse to man? Microbes Infect 5(8):749-756, 2003
25. Freston JW: Helicobacter pylori-negative peptic ulcers: frequency and implications for management. J Gastroenterol 35 (Suppl 12):29-32, 2000
26. Freston JW: Review article: role of proton pump inhibitors in non-H. pylori-related ulcers. Aliment Pharmacol Ther 15 (Suppl 2):2-5, 2001
27. Bonapace ES, Fisher RS, Parkman HP: Does fasting serum gastrin predict gastric acid suppression in patients on proton-pump inhibitors? Dig Dis Sci 45(1):34-39, 2000
28. Ellison EC, Sparks J: Zollinger-Ellison syndrome in the era of effective acid suppression: Are we unknowlingly growing tumors? Am J Surg 186(3):245-248, 2003
29. Kaneko E, Hoshihara Y, Sakaki N, Harasawa S, Ashida K, Asaka M, Asaki S, Nakamura T, Kobayashi K, Kajiyama G, Ogawa N, Yao T, Muto Y, Nakazawa S, Takemoto T: Peptic ulcer recurrence during maintenance therapy with H2-receptor antagonist following first-line therapy with proton pump inhibitor. J Gastroenterol 35(11):824-831, 2000
30. Corleto VD, Annibale B, Gibril F, Angeletti S, Serrano J, Venzon DJ, Delle Fave G, Jensen RT: Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome? Aliment Pharmacol Ther 15(10):1555-1561, 2001
31. Roy PK, Venzon DJ, Shojamanesh H, Abou-Saif A, Peghini P, Doppman JL, Gibril F, Jensen RT: Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore) 79(6):379-411, 2000
32. Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, Krenning EP, Bouillon R, Lamberts SW: Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol and Metab 82(8):2622-2628, 1997
33. Panzuto F, Severi C, Cannizzaro R, Falconi M, Angeletti S, Pasquali A, Corleto VD, Annibale B, Buonadonna A, Pederzoli P, Delle Fave G: Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J Endocrinol Invest 27(1):6-11, 2004
34. Wada M, Komoto I, Doi R, Imamura M: Intravenous calcium injection test is a novel complementary procedure in differential diagnosis for gastrinoma. World J Surg 26(10):1291-1296, 2002 (epub 9/4/02)
35. Metz DC, Soffer E, Forsmark CE, Cryer B, Chey W, Bochenek W, Pisegna JR: Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion. Am J Gastroenterol 98(2):301-307, 2003
36. Lew EA, Pisegna JR, Starr JA, Soffer EF, Forsmark C, Modlin IM, Walsh JH, Beg M, Bochenek W, Metz DC: Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology 118(4):696-704, 2000
37. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, Weber HC, Stewart CA, Jensen RT: Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 125(1):26-34, 1996
38. Gibril F, Reynolds JC, Doppman JL, et al.: Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: a prospective study. Ann Intern Med 125:26-34, 1996
39. Kisker O, Bartsch D, Weinel RJ, Joseph K, Welcke UH, Zaraca F, Rothmund M: The value of somatostatin-receptor scintigraphy in newly diagnosed endocrine gastroenteropancreatic tumors. J Am Coll Surg 184(5):487-492, 1997
40. Norton JA, Jensen RT: Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 240(5):757-773, 2004
41. Hung PD, Schubert ML, Mihas AA: Zollinger-Ellison syndrome. Curr Treat Opt Gastroenterol 6(2):163-170, 2003
42. Norton JA, Fraker DL, Alexander HR, Venzon DJ, Doppman JL, Serrano J, Goebel SU, Peghini PL, Roy PK, Gibril F, Jensen RT: Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 341(9):635-644, 1999